These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12904137)

  • 21. Comprehensive care for hemophilia and other inherited bleeding disorders.
    Page D
    Transfus Apher Sci; 2019 Oct; 58(5):565-568. PubMed ID: 31427262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 24. Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions.
    Levy-Mendelovich S; Livnat T; Barg AA; Kidon M; Brutman-Barazani T; Kenet G
    Blood Cells Mol Dis; 2020 Feb; 80():102370. PubMed ID: 31669933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgery in haemophilic patients with inhibitors.
    Rodriguez-Merchan EC
    Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039
    [No Abstract]   [Full Text] [Related]  

  • 26. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries.
    O'Mahony B; Noone D; Prihodova L
    Haemophilia; 2015 Jul; 21(4):436-43. PubMed ID: 25996253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
    Chuansumrit A; Sri-Udomporn N; Srimuninnimit V; Juntarukha R
    Haemophilia; 2001 Sep; 7(5):532-4. PubMed ID: 11554948
    [No Abstract]   [Full Text] [Related]  

  • 29. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
    Young G; McDaniel M; Nugent DJ
    Haemophilia; 2005 May; 11(3):203-7. PubMed ID: 15876264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Joint WFH-ISTH session: issues in clinical trial design.
    Peyvandi F; Farrugia A; Iorio A; Key NS; Srivastava A
    Haemophilia; 2014 May; 20 Suppl 4():137-44. PubMed ID: 24762289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Participation in research: the economic advantages in a haemophilia research population.
    Wasserman J; Ullman M; Cantini M; Moynihan K; Hoots WK
    Haemophilia; 2000 Sep; 6(5):571-4. PubMed ID: 11012704
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

  • 35. Issues in making a therapeutic choice: recombinant and/or human-derived products.
    Aledort LM
    Haemophilia; 2001 Jan; 7(1):89-90. PubMed ID: 11136386
    [No Abstract]   [Full Text] [Related]  

  • 36. rFVIIa (Novoseven): the new panacea?
    Ickx BE
    Acta Anaesthesiol Belg; 2003; 54(4):333-5. PubMed ID: 14719355
    [No Abstract]   [Full Text] [Related]  

  • 37. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
    Mancuso ME; Mahlangu JN; Pipe SW
    Lancet; 2021 Feb; 397(10274):630-640. PubMed ID: 33460559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
    Briët E; Mauser-Bunschoten EP
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of recombinant coagulation factors in treating hemophilia.
    Morfini M; Rapisarda CAP
    Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C; Young G
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.